154 related articles for article (PubMed ID: 38379744)
1. Direct long-acting antibodies: updating the language of RSV prevention to reflect the evolution of mAbs.
Lopalco PL; Esposito S; Martinón-Torres F; ; Checcucci Lisi G; Chung-Delgado K; Davidson B; Evans S; Patel A; Fellingham C; Pounds B; Harris C; Mukherjee T
J Prev Med Hyg; 2023 Dec; 64(4):E377-E381. PubMed ID: 38379744
[TBL] [Abstract][Full Text] [Related]
2. Parental knowledge about respiratory syncytial virus (RSV) and attitudes to infant immunization with monoclonal antibodies.
Lee Mortensen G; Harrod-Lui K
Expert Rev Vaccines; 2022 Oct; 21(10):1523-1531. PubMed ID: 35929971
[TBL] [Abstract][Full Text] [Related]
3. RSV Prevention in All Infants: Which Is the Most Preferable Strategy?
Esposito S; Abu Raya B; Baraldi E; Flanagan K; Martinon Torres F; Tsolia M; Zielen S
Front Immunol; 2022; 13():880368. PubMed ID: 35572550
[TBL] [Abstract][Full Text] [Related]
4. Immunization technologies: Time to consider new preventative solutions for respiratory syncytial virus infections.
Weil-Olivier C; Salisbury D; Navarro-Alonso JA; Tzialla C; Zhang Y; Esposito S; Midulla F; Tenenbaum T
Hum Vaccin Immunother; 2023 Dec; 19(1):2209000. PubMed ID: 37193673
[TBL] [Abstract][Full Text] [Related]
5. The clinical impact of multiple prevention strategies for respiratory syncytial virus infections in infants and high-risk toddlers in the United States.
Ektare V; Lang J; Choi Y; Finelli L
Vaccine; 2022 Oct; 40(42):6064-6073. PubMed ID: 36096968
[TBL] [Abstract][Full Text] [Related]
6. WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use.
Sparrow E; Adetifa I; Chaiyakunapruk N; Cherian T; Fell DB; Graham BS; Innis B; Kaslow DC; Karron RA; Nair H; Neuzil KM; Saha S; Smith PG; Srikantiah P; Were F; Zar HJ; Feikin D
Vaccine; 2022 Jun; 40(26):3506-3510. PubMed ID: 35184927
[TBL] [Abstract][Full Text] [Related]
7. Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis.
Maas BM; Lommerse J; Plock N; Railkar RA; Cheung SYA; Caro L; Chen J; Liu W; Zhang Y; Huang Q; Gao W; Qin L; Meng J; Witjes H; Schindler E; Guiastrennec B; Bellanti F; Spellman DS; Roadcap B; Kalinova M; Fok-Seang J; Catchpole AP; Espeseth AS; Stoch SA; Lai E; Vora KA; Aliprantis AO; Sachs JR
EBioMedicine; 2021 Nov; 73():103651. PubMed ID: 34775220
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of pharmaceutical strategies to prevent respiratory syncytial virus disease in young children: a decision-support model for use in low-income and middle-income countries.
Mahmud S; Baral R; Sanderson C; Pecenka C; Jit M; Li Y; Clark A
BMC Med; 2023 Apr; 21(1):138. PubMed ID: 37038127
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Infection.
Rodriguez-Fernandez R; Mejias A; Ramilo O
Pediatr Infect Dis J; 2021 May; 40(5S):S35-S39. PubMed ID: 34042909
[TBL] [Abstract][Full Text] [Related]
10. Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study.
Li Y; Hodgson D; Wang X; Atkins KE; Feikin DR; Nair H
Lancet Infect Dis; 2021 Sep; 21(9):1303-1312. PubMed ID: 33965062
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries.
Getaneh AM; Li X; Mao Z; Johannesen CK; Barbieri E; van Summeren J; Wang X; Tong S; Baraldi E; Phijffer E; Rizzo C; van Wijhe M; Heikkinen T; Bont L; Willem L; Jit M; Beutels P; Bilcke J;
Vaccine; 2023 Feb; 41(9):1623-1631. PubMed ID: 36737318
[TBL] [Abstract][Full Text] [Related]
12. Passive and active immunization against respiratory syncytial virus for the young and old.
Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
[TBL] [Abstract][Full Text] [Related]
13. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?
Munoz FM
Curr Opin Infect Dis; 2015 Jun; 28(3):221-4. PubMed ID: 25918956
[TBL] [Abstract][Full Text] [Related]
14. Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
Fleming-Dutra KE; Jones JM; Roper LE; Prill MM; Ortega-Sanchez IR; Moulia DL; Wallace M; Godfrey M; Broder KR; Tepper NK; Brooks O; Sánchez PJ; Kotton CN; Mahon BE; Long SS; McMorrow ML
MMWR Morb Mortal Wkly Rep; 2023 Oct; 72(41):1115-1122. PubMed ID: 37824423
[TBL] [Abstract][Full Text] [Related]
15. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.
Resch B
Hum Vaccin Immunother; 2017 Sep; 13(9):2138-2149. PubMed ID: 28605249
[TBL] [Abstract][Full Text] [Related]
16. Respiratory syncytial virus immunoglobulin and monoclonal antibodies in the prevention and treatment of respiratory syncytial virus infection.
Welliver RC
Semin Perinatol; 1998 Feb; 22(1):87-95. PubMed ID: 9523402
[TBL] [Abstract][Full Text] [Related]
17. RSV disease in infants and young children: Can we see a brighter future?
Baraldi E; Checcucci Lisi G; Costantino C; Heinrichs JH; Manzoni P; Riccò M; Roberts M; Vassilouthis N
Hum Vaccin Immunother; 2022 Nov; 18(4):2079322. PubMed ID: 35724340
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats.
Wyde PR; Moore DK; Hepburn T; Silverman CL; Porter TG; Gross M; Taylor G; Demuth SG; Dillon SB
Pediatr Res; 1995 Oct; 38(4):543-50. PubMed ID: 8559607
[TBL] [Abstract][Full Text] [Related]
19. Preparation and Evaluation of the Fully Humanized Monoclonal Antibody GD-mAb Against Respiratory Syncytial Virus.
Tian P; Wang Y; Liu H; Yang Y; Wu X; Wei H; Chen T
Front Cell Infect Microbiol; 2019; 9():275. PubMed ID: 31417879
[TBL] [Abstract][Full Text] [Related]
20. Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand.
Prasad N; Read JM; Jewell C; Waite B; Trenholme AA; Huang QS; Grant CC; Newbern EC; Hogan AB
Vaccine; 2021 Jul; 39(31):4383-4390. PubMed ID: 34147296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
